SLAMF7 and plasma cell myeloma: Following successful CS1-dbBiTE binding to positive targets, we examined the in vitro cytotoxic response of CS1-dbBiTE-armed, activated human T cells (1 μg/mL per 10×106 cells) against multiple myeloma line MM.1S.